Sanofi-Aventis Deutschland GmBH v. Glenmark Pharms. Inc. (Fed. Cir.)

by Robins Kaplan LLP

Case Name: Sanofi-Aventis Deutschland GmBH v. Glenmark Pharms Inc., 748 F.3d 1354 (Fed. Cir. Apr. 21, 2014) (Circuit Judges Newman, Linn and Wallach presiding; Opinion by Newman) (Appeal from D.N.J., Cavanaugh, J.)

Drug Product and Patent(s)-in-Suit: Tarka® (trandolapril/verapamil hydrochloride); U.S. Pat. No. 5,721,244 (“the ’244 patent”)

Nature of the Case and Issue(s) Presented:  The parties tried the issue of validity before a jury after Glenmark stipulated that its ANDA product would infringe the patent-in-suit. The jury found the ’244 patent valid and awarded Sanofi damages for Glenmark’s at risk launch. The trial court denied all post-trial motions and Glenmark appealed. Glenmark raised three arguments on appeal: (i) the ’244 patent was invalid; (ii) Glenmark was entitled to a new trial based on a prejudicial jury instruction on evidence spoliation; and (iii) that no damages should have been awarded due to lack of standing of the Abbott United States companies. The ’244 patent claims a pharmaceutical composition which is the combination of an angiotensin-converting enzyme inhibitor and a calcium antagonist. The asserted dependent claim identified the ACE inhibitor as trandolapril or quinapril. Glenmark argued that the jury finding could not stand because, as a matter of law, the claimed combination consisted of compounds that were already known and whose selection was obvious to try.

The Federal Circuit found substantial evidence to support the jury’s finding based on the structure of the ACE inhibitors. The district court concluded that Glenmark failed to preserve documents and instructed the jury to draw an adverse inference that electronic documents from 2005-2006 would have been unfavorable. Glenmark argued that the inference was improper because Sanofi did not make a showing that any deleted e-mails contained relevant evidence. The Federal Circuit was not persuaded because generic drug discussions occurred during the time period in question and found that the jury instruction was not an abuse of discretion. Finally, Glenmark challenged the standing of Abbott Laboratories (“Abbott”) and Abbott Laboratories, Inc. (“ALI”). Glenmark argued that since Abbott was not an exclusive licensee of the ’244 patent, it was not entitled to lost profits and price erosion damages. The Federal Circuit rejected this argument finding that the district court did not clearly err in finding that Abbott and ALI have exclusive rights in the United States under the ’244 patent.

Why Sanofi Prevailed:  The Federal Circuit rejected Glenmark’s obvious to try argument because of the structure of the ACE inhibitor. Trandolapril is a “double-ring” compound. At the time the patent was filed in 1986, the only FDA approved ACE inhibitors were single-ring inhibitors (enalapril and captopril). At trial, Glenmark’s expert testified that quinapril and trandolapril are in the double-ring class of ACE inhibitors and the prior art did not suggest using these compounds with a calcium channel blocker. The experts disagreed as to whether the ring structure mattered. Plaintiffs’ expert testified that generally one of skill in the art in 1986 would believe that the double ring was less effective than the single ring. But there was no disagreement that the prior art showed that ACE inhibitors and calcium blockers required more than once-a-day dosing and that the patented combination was more effective than the prior art. Glenmark argued that these results should not impact the obviousness analysis since they were discovered after the patent application was filed. The Federal Circuit rejected this argument outright noting that a patentability analysis may consider all of the characteristics of the invention, whenever they manifest. The Federal Circuit found that substantial evidence supported the jury’s finding of validity and that the jury could have relied on plaintiffs’ expert opinion that one of ordinary skill in the art would not have predicted longer lasting effects by double ring ACE inhibitors. The Federal Circuit also denied Glenmark’s motion for a new trial based on the spoilage jury instruction. The district court did not abuse its discretion with the adverse inference because the destroyed records were within an appropriate timeframe and there was no reasonable negation of the inference. Finally, the Federal Circuit affirmed the district court’s finding that Abbott and ALI have the exclusive right to market the brand name product and had standing to recover damages. The Federal Circuit noted that all of the entities in the license chain were joined in the suit and there was no danger of multiple suits. Abbott and ALI had an exclusive right to the patented product in the United States based on Abbott’s ownership of the NDA and relationships and agreements among the Plaintiffs.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.